Microcystic Lymphatic Malformation Clinical Trial
Official title:
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00975819 -
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
|
Phase 2 | |
Recruiting |
NCT06160739 -
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
|
||
Not yet recruiting |
NCT06239480 -
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
|
Phase 3 |